Literature DB >> 20124400

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

Glenn N Levine1, Anthony V D'Amico, Peter Berger, Peter E Clark, Robert H Eckel, Nancy L Keating, Richard V Milani, Arthur I Sagalowsky, Matthew R Smith, Neil Zakai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20124400      PMCID： PMC3049943          DOI： 10.3322/caac.20061

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


× No keyword cloud information.
  43 in total

1.  Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.

Authors:  L M Eri; P Urdal; A G Bechensteen
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

2.  Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction.

Authors:  I S Ockene; N H Miller
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

Review 3.  Endocrine treatment of prostate cancer.

Authors:  Teuvo Tammela
Journal:  J Steroid Biochem Mol Biol       Date:  2004-12-31       Impact factor: 4.292

4.  Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer.

Authors:  J A Tayek; D Heber; L O Byerley; B Steiner; J Rajfer; R S Swerdloff
Journal:  Metabolism       Date:  1990-12       Impact factor: 8.694

5.  Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

Authors:  M Pyörälä; H Miettinen; M Laakso; K Pyörälä
Journal:  Circulation       Date:  1998-08-04       Impact factor: 29.690

Review 6.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Authors:  Frances Dockery; Christopher J Bulpitt; Sanjiv Agarwal; Mandy Donaldson; Chakravarthi Rajkumar
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

9.  Hyperinsulinemia as an independent risk factor for ischemic heart disease.

Authors:  J P Després; B Lamarche; P Mauriège; B Cantin; G R Dagenais; S Moorjani; P J Lupien
Journal:  N Engl J Med       Date:  1996-04-11       Impact factor: 91.245

10.  Management of metastatic prostatic cancer.

Authors:  D F Paulson
Journal:  Urology       Date:  1985-02       Impact factor: 2.649
View more
  60 in total

1.  Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

Authors:  Nancy L Keating; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  Eur Urol       Date:  2012-04-19       Impact factor: 20.096

2.  Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies.

Authors:  A Zapatero; C González San Segundo; A Boladeras; A Gómez Caamaño; J López Torrecilla; X Maldonado
Journal:  Clin Transl Oncol       Date:  2014-09-03       Impact factor: 3.405

Review 3.  [Not Available].

Authors:  Imad Ziouziou; Tariq Karmouni; Khalid El Khader; Abdellatif Koutani; Ahmed Iben Attya Andaloussi
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

Review 4.  The status of surgery in the management of high-risk prostate cancer.

Authors:  Christian Bach; Sailaja Pisipati; Datesh Daneshwar; Mark Wright; Edward Rowe; David Gillatt; Raj Persad; Anthony Koupparis
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

5.  Predictors of recurrent hospital admissions among prostate cancer survivors.

Authors:  Jerome Gnanaraj; Zarish Umar; Shobana Balakrishnan; Lucia Ponor; Edward James Wright; Waseem Khaliq
Journal:  Med Oncol       Date:  2017-07-27       Impact factor: 3.064

6.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

Review 7.  A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.

Authors:  C Jin; Y Fan; Y Meng; C Shen; Y Wang; S Hu; C Cui; T Xu; W Yu; J Jin
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-09-06       Impact factor: 5.554

Review 8.  Locally advanced prostate cancer: optimal therapy in older patients.

Authors:  Michael Froehner; Manfred P Wirth
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

9.  Testosterone deficiency syndrome and cardiovascular health: An assessment of beliefs, knowledge and practice patterns of general practitioners and cardiologists in Victoria, BC.

Authors:  Christopher J D Wallis; Hilary Brotherhood; Peter J Pommerville
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

10.  Early life exposure to the 1918 influenza pandemic and old-age mortality by cause of death.

Authors:  Mikko Myrskylä; Neil K Mehta; Virginia W Chang
Journal:  Am J Public Health       Date:  2013-05-16       Impact factor: 9.308
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.